Longevity Health Shares Soar After Keeping Nasdaq Listing Ahead Merger

Dow Jones

May 22, 2025

By Adam L. Cataldo

Shares of Longevity Health Holdings rallied following a ruling that allows the company to maintain its listing on the Nasdaq stock exchange ahead of its proposed merger with 20/20 BioLabs.

The decision is dependent on meeting Nasdaq's initial listing rules once the deal is completed, Longevity said Wednesday.

The stock climbed 66% to $5.08 in postmarket trading after ending the regular session down 6.2% at $3.06. Shares fell to a 52-week low of $2.63 on May 14, and are down 96% in the past year.

Longevity and 20/20 executed a merger agreement last month in a deal that will lead to shareholders of 20/20 owning about 50.1% of the combined company. Once the merger is completed, Longevity said it plans to effect a 1-for-30 reverse stock split to address Nasdaq's listing requirements. The merger is expected to be completed on or before Sept. 2.

The Nasdaq Hearings Panel's decision was based on a review of both companies' financial statements and pro forma projections, Longevity said.

Pittsburgh-based Longevity describes itself as focused on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics and nutrition. 20/20 Biolabs develops and commercializes innovative laboratory tests for the early detection and the proactive management of chronic disease risk.

Write to Adam Cataldo at adam.cataldo@wsj.com

(END) Dow Jones Newswires

May 21, 2025 19:23 ET (23:23 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2537957776"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537957776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537957776?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-22 07:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537957776","market":"hk","top_or_hot":-1,"title":"Longevity Health Shares Soar After Keeping Nasdaq Listing Ahead Merger","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adam L. Cataldo \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Longevity Health Holdings rallied following a ruling that allows the company to maintain its listing on the Nasdaq stock exchange ahead of its proposed merger with 20/20 BioLabs. \n</p>\n<p>\n  The decision is dependent on meeting Nasdaq's initial listing rules once the deal is completed, Longevity said Wednesday. \n</p>\n<p>\n  The stock climbed 66% to $5.08 in postmarket trading after ending the regular session down 6.2% at $3.06. Shares fell to a 52-week low of $2.63 on May 14, and are down 96% in the past year. \n</p>\n<p>\n  Longevity and 20/20 executed a merger agreement last month in a deal that will lead to shareholders of 20/20 owning about 50.1% of the combined company. Once the merger is completed, Longevity said it plans to effect a 1-for-30 reverse stock split to address Nasdaq's listing requirements. The merger is expected to be completed on or before Sept. 2. \n</p>\n<p>\n  The Nasdaq Hearings Panel's decision was based on a review of both companies' financial statements and pro forma projections, Longevity said. \n</p>\n<p>\n  Pittsburgh-based Longevity describes itself as focused on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics and nutrition. 20/20 Biolabs develops and commercializes innovative laboratory tests for the early detection and the proactive management of chronic disease risk. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adam Cataldo at adam.cataldo@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 21, 2025 19:23 ET (23:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Longevity Health Shares Soar After Keeping Nasdaq Listing Ahead Merger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLongevity Health Shares Soar After Keeping Nasdaq Listing Ahead Merger\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-22 07:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adam L. Cataldo \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Longevity Health Holdings rallied following a ruling that allows the company to maintain its listing on the Nasdaq stock exchange ahead of its proposed merger with 20/20 BioLabs. \n</p>\n<p>\n  The decision is dependent on meeting Nasdaq's initial listing rules once the deal is completed, Longevity said Wednesday. \n</p>\n<p>\n  The stock climbed 66% to $5.08 in postmarket trading after ending the regular session down 6.2% at $3.06. Shares fell to a 52-week low of $2.63 on May 14, and are down 96% in the past year. \n</p>\n<p>\n  Longevity and 20/20 executed a merger agreement last month in a deal that will lead to shareholders of 20/20 owning about 50.1% of the combined company. Once the merger is completed, Longevity said it plans to effect a 1-for-30 reverse stock split to address Nasdaq's listing requirements. The merger is expected to be completed on or before Sept. 2. \n</p>\n<p>\n  The Nasdaq Hearings Panel's decision was based on a review of both companies' financial statements and pro forma projections, Longevity said. \n</p>\n<p>\n  Pittsburgh-based Longevity describes itself as focused on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics and nutrition. 20/20 Biolabs develops and commercializes innovative laboratory tests for the early detection and the proactive management of chronic disease risk. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adam Cataldo at adam.cataldo@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 21, 2025 19:23 ET (23:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":".IXIC","symbol_name":"NASDAQ Composite","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2537957776","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537957776","pubTimestamp":1747869780,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Longevity Health Holdings rallied following a ruling that allows the company to maintain its listing on the Nasdaq stock exchange ahead of its proposed merger with 20/20 BioLabs.The decision is dependent on meeting Nasdaq's initial listing rules once the deal is completed, Longevity said Wednesday.The stock climbed 66% to $5.08 in postmarket trading after ending the regular session down 6.2% at $3.06. Shares fell to a 52-week low of $2.63 on May 14, and are down 96% in the past year.Longevity and 20/20 executed a merger agreement last month in a deal that will lead to shareholders of 20/20 owning about 50.1% of the combined company. Once the merger is completed, Longevity said it plans to effect a 1-for-30 reverse stock split to address Nasdaq's listing requirements. The merger is expected to be completed on or before Sept. 2.Pittsburgh-based Longevity describes itself as focused on extending human longevity and healthy aging through innovative products in regenerative bio-ae","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{".IXIC":"NASDAQ Composite","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","XAGE":"Longevity Health Holdings, Inc.","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据"},"translate_title":"Longevity Health股价在纳斯达克上市合并后飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{".IXIC":1,"XAGE":0.9,"NDAQ":1,"NQmain":1},"content_text":"By Adam L. Cataldo \n\n\n \n\n\n  Shares of Longevity Health Holdings rallied following a ruling that allows the company to maintain its listing on the Nasdaq stock exchange ahead of its proposed merger with 20/20 BioLabs. \n\n\n  The decision is dependent on meeting Nasdaq's initial listing rules once the deal is completed, Longevity said Wednesday. \n\n\n  The stock climbed 66% to $5.08 in postmarket trading after ending the regular session down 6.2% at $3.06. Shares fell to a 52-week low of $2.63 on May 14, and are down 96% in the past year. \n\n\n  Longevity and 20/20 executed a merger agreement last month in a deal that will lead to shareholders of 20/20 owning about 50.1% of the combined company. Once the merger is completed, Longevity said it plans to effect a 1-for-30 reverse stock split to address Nasdaq's listing requirements. The merger is expected to be completed on or before Sept. 2. \n\n\n  The Nasdaq Hearings Panel's decision was based on a review of both companies' financial statements and pro forma projections, Longevity said. \n\n\n  Pittsburgh-based Longevity describes itself as focused on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics and nutrition. 20/20 Biolabs develops and commercializes innovative laboratory tests for the early detection and the proactive management of chronic disease risk. \n\n\n \n\n\n  Write to Adam Cataldo at adam.cataldo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 21, 2025 19:23 ET (23:23 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}